NCT04356716 is a Phase 2 clinical trial of Sildenafil in Choroidal Ischemia, sponsored by Columbia University.

Who is sponsoring NCT04356716?

NCT04356716 is sponsored by Columbia University.

What drugs are being tested in NCT04356716?

Interventions in NCT04356716: Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A), Visual Acuity (VA).

What condition does NCT04356716 study?

NCT04356716 studies Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa.

Is NCT04356716 still recruiting?

NCT04356716 is currently completed. Last updated 4 July 2025.

Are results published for NCT04356716?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-07-04 · How we verify

NCT04356716

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sildenafil for Treatment of Choroidal Ischemia

Completed Phase 2 Results posted Last updated 4 July 2025

What this trial tests

Phase 2 trial testing Sildenafil in Choroidal Ischemia in 22 participants. Completed in 18 February 2020.

Timeline

11 November 2014

Primary endpoint
18 February 2020

18 February 2020

Quick facts

Lead sponsor	Columbia University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	11 November 2014
Primary completion	18 February 2020
Estimated completion	18 February 2020
Sites	1 location across United States

Drugs / interventions tested

Sildenafil (sildenafil) — full drug profile →
Standard of Care Sildenafil
Ocular Coherence Tomography-Angiography (OCT-A)
Visual Acuity (VA)

Conditions studied

Choroidal Ischemia — all drugs for Choroidal Ischemia →
Vitelliform Macular Dystrophy — all drugs for Vitelliform Macular Dystrophy →
Age-related Macular Degeneration — all drugs for Age-related Macular Degeneration →
Central Serous Retinopathy — all drugs for Central Serous Retinopathy →

Sponsor

Columbia University

Who can join

18 and older, any sex, with Choroidal Ischemia or Vitelliform Macular Dystrophy. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Visual Acuity (Sildenafil Group) Primary · Up to 63 months

Patients are evaluated for progression of disease/dystrophy via visual acuity (improved/stable/worsened) and appearance of fluid layer and drusen on OCT testing.

Right eyes

Group	Value	95% CI
Sildenafil	0.00	± 0.21

Left eyes

Group	Value	95% CI
Sildenafil	-0.03	± 0.36

Change in Visual Acuity (Medical Record Review Group) Primary · 22 months

Patients are evaluated for progression of disease/dystrophy via visual acuity (improved/stable/worsened) and appearance of fluid layer and drusen on OCT testing.

Right eye

Group	Value	95% CI
Medical Record Review	0.00

Left eye

Group	Value	95% CI
Medical Record Review	0.00

Sponsor's own description

The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform degeneration, dry and reticular age-related macular degeneration (AMD) as well as patients with hereditary and acquired retinal dystrophies such as retinitis pigmentosa and central serous retinopathy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prospective Impact of Sildenafil on Chronic cEntral Serous Chorioretinopathy: PISCES Trial.
Breazzano MP, Coleman DJ, Chen RWS, Chang S, et al · · 2020 · cited 10× · PMID 32525054 · DOI 10.1016/j.oret.2020.06.006

Verify or expand the search:

Other trials of Sildenafil

Trials testing the same drug.

NCT07039760 — Asciminib With or Without Sildenafil for Brain Tumors · EARLY_PHASE1 · not yet recruiting
NCT06800092 — Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment · Phase 2, PHASE3 · not yet recruiting
NCT06954597 — Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis · Phase 2 · recruiting
NCT06778330 — The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonar · NA · completed
NCT06875258 — PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II) · Phase 4 · recruiting

Other Columbia University trials

Trials by the same sponsor.

NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · not yet recruiting
NCT07264582 — HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking · NA · not yet recruiting
NCT05992415 — Know Your Pressures NYC · NA · not yet recruiting
NCT05645211 — The AgRP and GH/IGF-1 Axis in Children · not yet recruiting
NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04356716 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Columbia University
Last refreshed: 4 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04356716.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing